Hansa Biopharma AB (publ) (OTCMKTS:HNSBF – Get Free Report) is one of 380 public companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Hansa Biopharma AB (publ) to related businesses based on the strength of its profitability, institutional ownership, dividends, risk, valuation, analyst recommendations and earnings.
Analyst Ratings
This is a summary of recent ratings for Hansa Biopharma AB (publ) and its peers, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Hansa Biopharma AB (publ) | 0 | 0 | 2 | 0 | 3.00 |
| Hansa Biopharma AB (publ) Competitors | 336 | 1318 | 3738 | 25 | 2.64 |
Hansa Biopharma AB (publ) presently has a consensus price target of $189.50, indicating a potential upside of 3,478.85%. As a group, “Biotechnology” companies have a potential upside of 93.55%. Given Hansa Biopharma AB (publ)’s stronger consensus rating and higher probable upside, analysts plainly believe Hansa Biopharma AB (publ) is more favorable than its peers.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Hansa Biopharma AB (publ) | N/A | N/A | N/A |
| Hansa Biopharma AB (publ) Competitors | -9,405.31% | -241.59% | -21.95% |
Institutional & Insider Ownership
26.5% of shares of all “Biotechnology” companies are held by institutional investors. 26.9% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Hansa Biopharma AB (publ) and its peers top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Hansa Biopharma AB (publ) | N/A | N/A | -6.12 |
| Hansa Biopharma AB (publ) Competitors | $111.74 million | -$12.13 million | 30.47 |
Hansa Biopharma AB (publ)’s peers have higher revenue, but lower earnings than Hansa Biopharma AB (publ). Hansa Biopharma AB (publ) is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Summary
Hansa Biopharma AB (publ) beats its peers on 6 of the 11 factors compared.
About Hansa Biopharma AB (publ)
-logo.png?v=20230214135653){kind=logo}
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments with rare immunological conditions using its proprietary enzyme technology platform. The company's lead drug candidate is Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the potential of combining imlifidase and efgartigimod to potentially be used in the acute and chronic setting of autoimmune diseases and transplantation. It also has a collaboration with Genethon to develop imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Receive News & Ratings for Hansa Biopharma AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hansa Biopharma AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.
-inc-logo.PNG?v=20210312142656&h=45&w=95&zc=2){kind=logo}
